Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib in Neoadjuvant NSCLC
NCT02271906Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2015
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib in non-small cell lung cancer (NSCLC), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Number of Patients With Treatment Completed. Started Jul 2015; status: terminated.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02271906.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02271906.